Invest
How It Works
Discover
Blog FAQs Market Insights Unicorn News Help Center
About
Get Started
Sign In
Menu Close

Limited Time Offer

Get $1000 towards your
first investment 

Start investing in private markets with Linqto – your access to disruptive startups and pre-IPO companies.

*Terms and conditions apply. See details

Get Your Offer Button Arrow
Lintqo CTA Lines

Tempus IPO

Internet

tempus.com
Sign Up to Invest

Summary*

Tempus, a Chicago-based precision medicine company founded in 2015, uses artificial intelligence to analyze medical data and develop personalized treatment options for patients. The company, led by billionaire Eric Lefkofsky, has raised over $1.3 billion in funding and was last valued at $8.1 billion in 2020. Tempus recently completed its initial public offering (IPO) on the Nasdaq, raising $410.7 million by pricing its shares at $37, the top of its marketed range. This gives the company a market value of approximately $6.1 billion.

The company's IPO comes amid growing investor interest in AI-powered healthcare solutions. Tempus has expanded beyond its initial focus on oncology to areas including cardiology, psychiatry, and infectious diseases. Its platform is used by thousands of physicians and researchers, as well as most major pharmaceutical companies.

Tempus reported $532 million in revenue for 2023, a 66% increase from the previous year. However, the company is not yet profitable, posting a net loss of $214 million in 2023. The IPO proceeds are expected to be used for general corporate purposes, including potential acquisitions and investments in technology.

The successful public debut of Tempus could pave the way for other AI healthcare companies to consider going public. However, the company will need to demonstrate a path to profitability and continued growth to maintain investor confidence in the competitive and rapidly evolving healthcare technology sector.

Get $1000 towards your
first investment 

*Terms and conditions apply. See details

Get Your Offer Button Arrow
Lintqo CTA Lines

How to invest in Tempus

While Tempus's IPO prospects remain uncertain, investors eager to gain exposure to innovative healthcare technology companies don't have to wait. At Linqto, we offer members access to interests in promising pre-IPO private companies, including potential leaders in the healthcare and AI sectors. Our platform allows you to diversify your portfolio with lower minimum investments, potentially benefiting from the growth of emerging industry disruptors like Tempus before they go public.

Sources

1 - Yahoo Entertainment - Tempus AI (TEM) made its trading debut on the Nasdaq via an IPO. The stock has popped in Friday trading after opening at $37 per share. Market Domination...

2 - Techmeme.com - Amy Or / Bloomberg:nTempus, which uses AI to process medical data, raised $410.7M after pricing its IPO at $37 a share, the top of a marketed range, giving it a $6.1B market value  —  (Updates with statement in second paragraph.)

3 - Forbes - Plus: Health tech company Tempus’ IPO

4 - Forbes - Lefkofsky, the founder and CEO of Tempus, spoke with Forbes about the IPO and the company, which is built on a massive trove of AI-trained patient and genomic data.

5 - Biztoc.com - IPO for Chicago AI health tech firm Tempus launches Crain's Chicago BusinessnEx-Groupon CEO raises $411 million in IPO for medicine data company AxiosnTempus Announces Pricing of Initial Public Offering Yahoo FinancenTempus AI IPO: stock price today, Nasdaq t…

*These comments should not be interpreted to mean that the company is formally pursuing or foregoing an IPO. The information provided above is based on current online discussions and is not intended as investment advice. Linqto does not endorse or guarantee the accuracy of this information, and we strongly recommend conducting your own research or consulting with a professional advisor before making any investment decisions. Linqto cannot be held liable for any investment outcomes resulting from the use of this information.